Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
March 3, 2026
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma
BM
Brigida Anna Maiorano
ND
Nazli Dizman
The University of Texas MD Anderson Cancer Center
AN
Andrea Necchi
Vita-Salute San Raffaele University
Key Points
Advanced urothelial carcinoma shows promise with emerging anti-HER2 therapies, enhancing patient care.
Significant improvements in clinical outcomes noted for patients treated with these targeted therapies.
Comprehensive review of therapeutic development highlights the vital role of biomarkers for patient stratification.
Implications call for further research to validate these therapies and explore combination treatments.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Maiorano et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7688fbadf0bb9e87e51b6
https://doi.org/https://doi.org/10.1016/j.eururo.2026.01.027
Contextualiser le développement des thérapies anti-HER2 pour les patients atteints de carcinome urothélial avancé | Synapse